trastuzumab duocarmazine

Trastuzumab duocarmazine is an investigational antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers, primarily unresectable locally advanced or metastatic breast cancer. It consists of a humanized monoclonal antibody (trastuzumab) targeting HER2 linked via a cleavable valine-citrulline linker to a cytotoxic payload (duocarmycin derivative). Upon binding to HER2 on tumor cells, the ADC is internalized and the linker is cleaved by proteases inside the cell, releasing active duocarmycin that induces DNA damage and cell death. The drug also leverages immune-mediated mechanisms through its trastuzumab component[1][4][5]. Developed by Byondis B.V., it has shown improved progression-free survival over standard chemotherapy in phase 3 trials but has not yet received regulatory approval due to outstanding questions from health authorities[3][7][10].

Brand names

JivadcoSYD985SYD-985SYD 985

Other names

immunoglobulin g1-kappa anti-(homo sapiens erbb2)humanized monoclonal antibody conjugated to the pro-drug seco-duocarmycinhydroxybtrastuzumab-duocarmazine